| NASDAQ (usa) |
 |
6715.56 | -12.11 | -0.18% |
| FTSE 100 (london) |
|
7487.96 | -5.12 | -0.07% |
| DAX (german) |
 |
13465.51 | 235.94 | 1.78% |
| NIKKEI 225 (japan) |
|
22420.08 | 408.47 | 1.86% |
| Hang - Seng (hong kong) |
|
28594.06 | 348.52 | 1.23% |
| NIFTY - 50 (india) | ||||
| Straits Times (singapore) |
|
3391.61 | 17.53 | 0.52% |
| KOSPI (korea) |
|
2556.47 | 33.04 | 1.31% |
| All Ordinaries (australia) |
|
6005.30 | 28.90 | 0.48% |
| BOVESPA (brazil) |
|
74092.76 | -215.73 | -0.29% |
Landos Biopharma Inc (NASDAQ: LABP)
LABP Technical Analysis
3
| As on 9th Jun 2023 LABP STOCK Price closed @ 4.07 and we RECOMMEND Buy for LONG-TERM with Stoploss of 1.45 & Buy for SHORT-TERM with Stoploss of 3.33 we also expect STOCK to react on Following IMPORTANT LEVELS. |
LABPSTOCK Price
| Open | 3.72 | Change | Price | % |
| High | 4.20 | 1 Day | 0.33 | 8.82 |
| Low | 3.48 | 1 Week | 1.31 | 47.46 |
| Close | 4.07 | 1 Month | 3.79 | 1353.57 |
| Volume | 85456 | 1 Year | -0.88 | -17.78 |
| 52 Week High 5.49 | 52 Week Low 0.22 | ||||
NASDAQ USA Most Active Stocks
| TSLA | 244.40 | 4.06% |
| TTOO | 0.07 | -12.50% |
| SOFI | 8.18 | 0.74% |
| FFIE | 0.33 | 6.45% |
| PONO | 1.72 | 2.38% |
| AMD | 124.92 | 3.20% |
| IDEX | 0.06 | 0.00% |
| NKLA | 0.70 | 14.75% |
| AMZN | 123.43 | -0.66% |
| AAPL | 180.96 | 0.22% |
NASDAQ USA Top Gainers Stocks
NASDAQ USA Top Losers Stocks
| LABP Daily Charts |
LABP Intraday Charts |
Whats New @ Bazaartrend |
LABP Free Analysis |
|
|
LABP Important Levels Intraday
| RESISTANCE | 5.46 |
| RESISTANCE | 5.01 |
| RESISTANCE | 4.74 |
| RESISTANCE | 4.46 |
| SUPPORT | 3.68 |
| SUPPORT | 3.40 |
| SUPPORT | 3.13 |
| SUPPORT | 2.68 |
LABP Forecast April 2024
| 4th UP Forecast | 9.79 |
| 3rd UP Forecast | 7.96 |
| 2nd UP Forecast | 6.82 |
| 1st UP Forecast | 5.69 |
| 1st DOWN Forecast | 2.45 |
| 2nd DOWN Forecast | 1.32 |
| 3rd DOWN Forecast | 0.18 |
| 4th DOWN Forecast | -1.65 |
LABP Weekly Forecast
| 4th UP Forecast | 6.23 |
| 3rd UP Forecast | 5.54 |
| 2nd UP Forecast | 5.11 |
| 1st UP Forecast | 4.68 |
| 1st DOWN Forecast | 3.46 |
| 2nd DOWN Forecast | 3.03 |
| 3rd DOWN Forecast | 2.60 |
| 4th DOWN Forecast | 1.91 |
LABP Forecast2024
| 4th UP Forecast | 14.75 |
| 3rd UP Forecast | 11.32 |
| 2nd UP Forecast | 9.21 |
| 1st UP Forecast | 7.09 |
| 1st DOWN Forecast | 1.05 |
| 2nd DOWN Forecast | -1.07 |
| 3rd DOWN Forecast | -3.18 |
| 4th DOWN Forecast | -6.61 |
Landos Biopharma Inc ( NASDAQ USA Symbol : LABP )
Sector : Healthcare And Other Stocks in Same Sector
Sector : Healthcare And Other Stocks in Same Sector
LABP Business Profile
Landos Biopharma, Inc., a clinical-stage biopharmaceutical company, discovers and develops oral therapeutics for patients with autoimmune diseases. Its lead product candidate in development is BT-11, an oral lanthionine synthetase C-like protein 2 (LANCL2) agonist for the treatment of ulcerative colitis (UC), Crohn's disease (CD), and inflammatory bowel diseases. The company also develops NX-13, a gut-restricted oral therapeutic that targets NOD-like receptor X1, a mitochondria-associated receptor associated with the modulation of inflammatory cytokines for UC and CD; and PX-69, an oral PLXDC2 agonist for the treatment of diabetic nephropathy and rheumatoid arthritis. Landos Biopharma, Inc. was incorporated in 2017 and is headquartered in Blacksburg, Virginia. Address: 1800 Kraft Drive, Blacksburg, VA, United States, 24060-6370
© 2005-2023 BazaarTrend.com All rights reserved.
Data and information is provided for informational purposes only, and is not intended for trading purposes.
Neither BazaarTrend.com website nor any of its promoters shall be liable for any errors
or delays in the content, or for any actions taken in reliance thereon. Your use of this website constitutes
acceptance of our Terms Of Service
Data and information is provided for informational purposes only, and is not intended for trading purposes.
Neither BazaarTrend.com website nor any of its promoters shall be liable for any errors
or delays in the content, or for any actions taken in reliance thereon. Your use of this website constitutes
acceptance of our Terms Of Service